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ABSTRACT
Background Observational studies have suggested that 
patients with rheumatoid arthritis (RA) who experience 
inadequate response to anti-tumour necrosis factor 
(anti-TNF) agents respond more favourably to rituximab 
(RTX) than to an alternative anti-TNF agent. However, 
the relative effectiveness of these agents on long-term 
outcomes, particularly in radiographic damage, remains 
unclear.
Objective To compare the effectiveness of RTX against 
anti-TNF agents in preventing joint damage in patients 
with RA who have experienced inadequate response to at 
least one prior anti-TNF agent.
Methods This is a prospective cohort study within the 
Swiss registry of patients with RA who discontinued 
at least one anti-TNF agent and subsequently received 
either RTX or an alternative anti-TNF agent. The primary 
outcome, progression of radiographic joint erosions 
(Ratingen erosion score)over time, and the secondary 
outcome, functional disability (Health Assessment 
Questionnaire Disability Index), were analysed using 
regression models for longitudinal data and adjusted for 
potential confounders.
Results Of the 371 patients included, 104 received 
RTX and 267 received an alternative anti-TNF agent. 
During the 2.6-year median follow-up period, the rates 
of Ratingen erosion score progression were similar 
between patients taking RTX and patients taking an 
alternative anti-TNF agent (p=0.67). The evolution of the 
Health Assessment Questionnaire score was statistically 
signifi cantly better in the RTX group (p=0.016), but 
the magnitude of the effect was probably not clinically 
relevant.
Conclusion This observational study suggests that 
RTX is as effective as an alternative anti-TNF agent 
in preventing erosions in patients with RA who have 
previously experienced inadequate response to anti-TNF 
agents.
INTRODUCTION
Over the last decade, remarkable advances in the 
treatment of rheumatoid arthritis (RA) have been 
achieved, mostly owing to new anti-rheumatic 
treatments. The current anti-rheumatic armamen-
tarium in RA includes several synthetic disease-
modifying anti-rheumatic drugs (DMARDs) and 
nine approved biological agents. However, more 
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choices also lead to new challenges. One of these 
challenges is selecting the best treatment for an indi-
vidual patient and pondering the potential beneﬁ ts 
against the possible harms of a particular interven-
tion in a given clinical setting. A recent conference 
aimed to identify major gaps in our current clinical 
knowledge of RA management and listed ‘the com-
parison of active anti-rheumatic treatment options 
in patients for whom at least one tumour necrosis 
factor (TNF) inhibitor has failed’ as one of the key 
areas for clinical investigation.1
Comparative effectiveness research in RA is still 
in its infancy; the positioning of newer biological 
agents, in particular, has not been fully established.2
The only published randomised controlled trial 
(RCT) to indirectly compare two biological agents 
has been the ATTEST trial (‘Abatacept or inﬂ iximab 
versus placebo, a Trial for Tolerability, Efﬁ cacy and 
Safety in Treating RA’),3 which evaluated a T cell 
costimulation blocker against a TNF inhibitor (anti-
TNF) in patients who have failed methotrexate 
treatment. Lacking head-to-head trials comparing 
biological agents, we have used observational stud-
ies to examine comparative effectiveness despite 
their susceptibility to selection biases and confound-
ing factors. In particular, several cohort studies have 
analysed the effectiveness of switching to a second 
anti-TNF agent, compared to switching to a biologi-
cal agent with a different mechanism of action, in 
patients who have experienced inadequate response 
to previous anti-TNF agents.4–10 A meta-analysis 
concluded that switching to rituximab (RTX) was 
slightly more effective than maintaining drug class 
by switching to a second anti-TNF agent in reaching 
American College of Rheumatology 70% improve-
ment criteria or a disease activity score remission 
response.11 Some studies have suggested that the 
relative beneﬁ t of RTX over an anti-TNF agent was 
restricted to patients switching due to the ineffec-
tiveness of prior anti-TNF agents, but published 
results are essentially limited to only short-term 
outcomes such as RA disease activity. Long-term 
outcomes, such as structural joint damage or dis-
ability, may however be more relevant to chronic 
conditions such as RA and remain a concern. 
Prevention of structural damage has been suggested 
as the gold standard for drug studies in RA.12 Anti-
TNF agents have demonstrated outstanding efﬁ cacy 
in preventing radiographic joint damage even when 
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from non-academic centres and 20% from academic centres. 
The analysis included data collected from March 1996 through 
November 2010. The estimated proportion of Swiss patients 
with RA having biotreatment was around 13% in 2008, in line 
with other western European countries.18
RTX has been approved for the treatment of moderate to severe 
cases of RA only after the failure of anti-TNF agents. We therefore 
restricted the eligibility criteria for this analysis to patients who 
discontinued at least one anti-TNF agent (inﬂ iximab, etanercept, 
adalimumab, golimumab or certolizumab) and subsequently initi-
ated either an alternative anti-TNF agent or a ﬁ rst course of RTX. 
Thus, patients receiving anti-TNF or RTX treatment as their ﬁ rst 
biotreatment were excluded from the analysis. Other inclusion cri-
teria were a diagnosis of RA by a board-certiﬁ ed rheumatologist 
and the availability of at least two consecutive sets of radiographs. 
Because radiographs should reﬂ ect structural joint damage occur-
ring during the treatment of interest, we excluded radiographs that 
preceded the initiation of treatment by more than 6 months. The 
only exclusion criterion was RTX treatment for lymphoma.
The duration of drug exposure is not always clear-cut for biotreat-
ments, particularly for RTX, and patients can be lost to follow-up 
after varying durations, affecting the period of drug exposure.19 
Performing an ‘on-drug-only’ analysis or a ‘completers-only’ analy-
sis (ie, including only the patients with at least two consecutive sets 
of radiographs taken during exposure to the drug of interest) carries 
the risk of overestimating the true treatment effect, as only patients 
with satisfactory responses to treatment will remain on treatment 
long enough to have two radiographic assessments. To avoid this 
bias, we operationally deﬁ ned drug exposure at the initiation of the 
new treatment, whether or not patients continued to receive their 
initial treatment. This is a conservative approach comparable to an 
intent-to-treat analysis in randomised trials. In sensitivity analysis, 
we considered an alternative deﬁ nition for drug exposure (‘on drug 
only’, with observations censored after treatment interruption) 
according to recently published recommendations.19
the clinical response was not satisfactory,13 while inhibition of 
structural joint damage by RTX was initially perceived as less 
impressive,14 probably owing to different patient populations.
The aim of this analysis was to examine the effectiveness 
of switching to an alternative anti-TNF agent versus initiating 
RTX on long-term outcomes such as radiographic damage pro-
gression and functional disability. Both biological agents have 
established efﬁ cacy in preventing radiographic damage in place-
bo-controlled RCTs15 16 but have never been compared directly 
for their efﬁ cacy in this key outcome.
METHODS
Study design
We performed a nested cohort study to examine the impact of 
switching to an alternative anti-TNF agent versus RTX in patients 
with active RA and the impact of inadequate response to at least 
one previous anti-TNF agent. The study’s predeﬁ ned primary 
outcome was evolution of joint erosions. Ethical approval for the 
enrollment of patients into the Swiss Clinical Quality Management 
(SCQM) programme and related studies was obtained from the 
Swiss Academy of Medical Sciences review board.
Study population
SCQM-RA is a Swiss cohort of patients with RA that has been 
described in detail elsewhere.17 Patients are assessed at regular 
intervals for disease activity, radiographic erosions, past and 
current anti-rheumatic treatments, reasons for changes in treat-
ment, adverse events and RA symptoms.17 The Swiss regulatory 
authorities perform continuous monitoring of all patients with 
arthritis who are taking biological agents within the SCQM pro-
gramme; therefore, the cohort can be considered a representa-
tive population-based sample of Swiss patients with RA having 
biotreatment. SCQM patients come from a range of clinical set-
tings, with more than 50% enrolled by private practices, 30% 
Table 1 Baseline patient and treatment characteristics
Disease characteristics RTX (n=155)
Alternative anti-TNF 
agent (n=163) p
Age (years), median (IQR) 58 (47–66) 56 (44–64) 0.15
Male sex (%) 25 19 0.18
ACPA (%)* 81 74 0.30
RF (%) 92 82 0.01
Disease duration (years), mean (SEM) 12 (0.8) 11 (0.5) 0.13
Disease activity (DAS28), mean (SEM) 4.7 (0.14) 4.2 (0.08) 0.003
Radiographic erosion score
 Ratingen erosion score (0–190), mean (SEM) 34.9 (3.2) 32.5 (2.3) 0.64
 ERO%, mean (SEM) 18.1 (1.7) 17.1 (1.2) 0.64
Health Assessment Questionnaire (0-3), mean (SEM) 1.27 (0.07) 1.13 (0.04) 0.07
Concomitant use of DMARDs (%) 74 79 0.30
 Methotrexate (%) 34 46 0.03
 Lefl unomide (%) 14 20 0.15
 Other DMARDs (%)† 8 9 0.61
 Glucocorticoids (%) 56 48 0.16
Previous anti-TNF agents (n)
 Median (IQR) 1 (1–2) 1 (1–1) <0.001
 Mean (SD) 1.43 (0.6) 1.01 (0.12) <0.001
Time since the discontinuation of previous anti-TNF agent 
(months), median (IQR)
1 (0.1–4.0) 1.8 (0.5–13.6) 0.004
Percentages indicate the use of each cotreatment at baseline. Patients could receive more than one DMARD cotreatment, explaining 
why the sum of individual DMARDs may exceed 100%.
*Available for only half of all patients.
†Other DMARDs included synthetic DMARDs such as hydroxychloroquine, sulfasalazine and azathioprine.
ACPA, anti-citrullinated protein antibody; DAS28, Disease Activity Score based on 28 joints; DMARDs, disease-modifying anti-
rheumatic drugs (including oral glucocorticoids); ERO %, Ratingen erosion score expressed in per cent maximum erosion score; RF, 
rheumatoid factor; RTX, rituximab; TNF, tumour necrosis factor; IQR, interquartile ranges; SEM, standard error of the mean.
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Outcomes
The primary end point of this analysis was radiographic erosion 
progression as measured by the change in radiographic scores from 
baseline. A validated scoring method (Ratingen erosion score)20
was used to grade serial radiographs according to the number and 
the size of bone erosions. The Ratingen scoring method has good 
reliability, with an intrarater intraclass correlation coefﬁ cient (ICC) 
of 0.8–0.9 and an inter-rater ICC of 0.7–0.9, and is less susceptible 
to ceiling effects in advanced disease because of a true ordinal rating 
system.20 21 The minimal detectable radiographic change for this 
method has been determined to be around 3.3% of the maximum 
score.20 Radiographic damage was assessed prospectively by two 
independent assessors who were blinded to clinical information. 
Their reliability was good, with an intrareader ICC of 0.83 and 
an inter-rater ICC of between 0.83 and 0.96.22 The average of the 
two assessors’ change scores was used for the analysis. Ratingen 
erosion score can be expressed both in the original unit (Ratingen, 
range 0–190) and in per cent maximum damage score (ERO%).
A secondary study end point was the evolution of functional 
disability, measured as a change in the Health Assessment 
Questionnaire Disability Index (HAQ-DI) from baseline.23 The 
Health Assessment Questionnaire (HAQ) score ranges from 
0 to 3, with 3 representing the maximum possible disability. 
Furthermore, important baseline predictors of RA disease pro-
gression, such as demographic characteristics, various disease 
characteristics, concomitant treatment with DMARD and self-
assessed questionnaires, were extracted from the SCQM-RA 
database and used to assess the comparability of the patient 
groups and to adjust the analysis.
Analysis
Based on a previous analysis, we calculated that 320 patients 
(with a 2:1 ratio of anti-TNF-agent-treated patients to RTX-
treated patients) would be required to demonstrate a similar 
difference in radiographic progression,24 a type I error probabil-
ity of 0.05 and a statistical power of 80%. Baseline disease and 
treatment characteristics were compared using conventional 
descriptive statistics. The signiﬁ cance of differences in baseline 
disease characteristics was assessed with Student t test for nor-
mally distributed mean values of continuous variables and with 
Kruskal–Wallis test for non-normally distributed variables. For 
dichotomous variables, Pearson’s chi-square test was used to 
evaluate the statistical signiﬁ cance of differences in proportions. 
Drug retention was examined using survival analysis, and dif-
ferences in drug survival were explored with a Cox proportional 
hazard model. In order to minimise potential biases induced by 
sporadically missing covariates (≤5%), we used the population 
average as substitute. Statistical tests were two-sided and were 
evaluated at the 0.05 signiﬁ cance level. The analysis was per-
formed with STATA V. 11 (Stata Statistical Software, College 
Station, Texas, USA).
In observational studies, selection bias is always of concern 
because assignment to RTX versus alternative TNFs is not per-
fomed randomly. Because differences in disease characteristics 
may substantially inﬂ uence subsequent radiographic progres-
sion, we used multivariate regression models to adjust for poten-
tial confounding factors. The ﬁ nal adjusted model was adjusted 
for age, sex, rheumatoid factor (RF) positivity, disease duration, 
functional disability (HAQ), disease activity (Disease Activity 
Score based on 28 joints (DAS28)), time since discontinuation 
of previous anti-TNF agent, radiographic damage at baseline, 
use of low-dose glucocorticoid, concomitant use of synthetic 
DMARD, number of prior anti-TNF agent failures and primary 
failure of the previous anti-TNF agent (deﬁ ned as discontinua-
tion within the ﬁ rst 6 months). The evolution of radiographic 
erosions or functional disability outcomes was analysed using 
generalised mixed models for longitudinal data. We ﬁ rst selected 
the best-ﬁ tting model without controlling for potential con-
founders. We then adjusted the analysis for differences in base-
line disease characteristics using a multivariate model (adjusted 
model). We explored potential effect modiﬁ cation by concomi-
tant DMARD treatment, concomitant glucocorticoid treatment, 
RF positivity and primary failure of the previous anti-TNF agent 
Figure 1 Evolution of radiographic damage after the initiation of an 
alternative tumour necrosis factor (TNF) inhibitor versus rituximab 
(RTX; open diamond with a red line across). The change in radiographic 
damage score (Ratingen erosion score and ERO%) from baseline over 
the average follow-up period is represented for patients treated with 
RTX or with an alternative TNF inhibitor (alternative anti-TNF agent: 
open square with a black line across). The progression trajectories 
depicted are adjusted for baseline disease characteristics, in particular 
baseline ERO, disease activity and treatment characteristics. ERO% 
expresses the Ratingen erosion score in per cent maximum damage 
score. Ratingen expresses the erosion score in the original scale 
(0–190). Vertical lines represent the 95% CI of the mean for the anti-TNF 
group. Alternative anti-TNF agent represents a second, third or fourth 
TNF inhibitor.
Figure 2 Probability plot of radiographic damage progression with 
alternative tumour necrosis factor inhibitors versus rituximab. Probability 
plot of the individual rates of radiographic damage progression over 1 
year with the two drugs. The X axis displays cumulative probability, and 
the Y axis displays the rate of radiographic damage progression over 1 
year. Radiographic progression is assessed using the Ratingen erosion 
score expressed in per cent maximum damage score (ERO%). The 
horizontal line represents the absence of progression.
annrheumdis-2011-201016.indd   3 8/6/2012   10:58:08 AM
1682 Ann Rheum Dis 2012;71:1680–1685. doi:10.1136/annrheumdis-2011-201016
 group.bmj.com on November 15, 2012 - Published by ard.bmj.comDownloaded from 
Clinical and epidemiological research
 
using interaction terms. We produced a cumulative probability 
plot with the individual rates of radiographic progression over a 
1-year period based on the above model estimates.
RESULTS
A total of 650 patients with RA in the SCQM-RA database 
were taking an alternative anti-TNF agent or RTX after an ini-
tial inadequate response to anti-TNF agents and had at least one 
radiographic assessment while having this treatment. Of these, 
371 patients (57%) had subsequent radiographic assessments, 
leaving available for evaluation 104 patients taking RTX and 
267 patients taking an alternative anti-TNF agent. The patients 
excluded from the analysis initiated their biotreatment signiﬁ -
cantly later (1.9 years, p<0.001) but had otherwise mostly simi-
lar disease characteristics (supplemental ﬁ le), suggesting that 
missing follow-up time was the main reason for the absence 
of subsequent radiographs in these patients. The 371 patients 
matching the inclusion criteria had means of 2.8 radiographic 
assessments and 4.7 HAQ assessments during a median follow-
up period of 2.6 years (IQR 1.6–3.6). The median period of drug 
retention (‘drug survival’) was 3.43 years, which was not signiﬁ -
cantly different between the two groups (p=0.16).
Patients taking RTX received a median number of two cycles 
of RTX (a cycle consisting of two infusions of 1000 mg each, 
with concomitant use of glucocorticoids) in accordance with the 
manufacturer’s recommendations. Fifty-one per cent of patients 
taking an alternative anti-TNF agent received adalimumab (40 
mg subcutaneously every 2 weeks), 25% received etanercept (50 
mg per week), 16% received inﬂ iximab (3 mg/kg intravenously) 
and 8% received either golimumab or certulizumab. Some dif-
ferences between the RTX group and the alternative anti-TNF 
group were noted (table 1). Combination with methotrexate was 
more frequent in patients treated with an anti-TNF agent than 
in patients treated with RTX, but overall DMARD use was not 
signiﬁ cantly different between the two groups. Patients treated 
with RTX were more often positive for RF or anti-citrullinated 
protein antibody, had higher baseline DAS28 levels (4.7 vs 4.2), 
had a shorter interval between discontinuing the prior anti-
TNF agent and starting the new biotreatment (1 vs 1.8 months) 
and failed more prior anti-TNF agents (1.4 vs 1). RTX was the 
second biological agent in 52% of patients, the third biological 
agent in 39% of patients and the fourth biological agent in 9% 
of patients; anti-TNF agent was the second biological agent in 
80% of patients, the third biological agent in 18% of patients 
and the fourth or ﬁ fth biological agent in 2% of patients. Other 
important prognostic markers for radiographic progression, in 
particular baseline radiographic erosion scores and functional 
disability (HAQ) scores, were similar.
While the evolution of disease activity (DAS28) was signiﬁ -
cantly better in the RTX-treated group (at 1 year, incremental 
DAS28 improvement −0.34 (95% CI −0.14 to −0.53)) as previ-
ously demonstrated,4 the longitudinal evolution of radiographic 
erosions was similar between the RTX group and the alternative 
anti-TNF group (p=0.67; ﬁ gure 1). Overall, ERO% progressed, on 
average, by 0.23% (95% CI −0.22 to +0.69; Ratingen +0.44 (95% 
CI −0.42 to +1.31)) during the ﬁ rst year, representing approxi-
mately one new erosion in 2 years of follow-up or a low level 
of damage progression.20 ERO% progression with an alternative 
anti-TNF agent was 0.25% (95% CI −0.06 to +0.57; Ratingen 
+0.48 (95% CI −0.11 to +1.08)) during the ﬁ rst year after the 
switch, compared to 0.23% (95% CI −0.41 to +0.88; Ratingen 
+0.44 (95% CI −0.76 to +1.67)) with RTX. This means that 33% 
(34/104) of all patients taking RTX have presented at least one 
new erosion over a period of 1 year compared to 30% (81/266) 
of patients taking an alternative anti-TNF agent (p=0.68; ﬁ gure 
2). Signiﬁ cant predictors of subsequent radiographic progression 
were baseline ERO% level and high disease activity. We found 
no effect modiﬁ cation by concomitant use of DMARD (p=0.18), 
use of low-dose oral glucocorticoid use (p=0.26), RF seroposi-
tivity (p=0.79) or a personal history of primary anti-TNF agent 
failure (0.20). A sensitivity analysis with an alternative deﬁ nition 
of drug exposure (‘on drug only’) did not qualitatively change 
the conclusions (supplemental ﬁ le).
The longitudinal evolution of functional disability was sta-
tistically signiﬁ cantly better in the RTX group compared to the 
alternative anti-TNF group (p=0.015; ﬁ gure 3); however, the dif-
ference was far from reaching a minimally clinically important 
difference, estimated to be at least 0.22 HAQ-DI units.25 The 
HAQ-DI score improved by 0.05 HAQ units (95% CI −0.017 to 
+0.11) more on RTX 1 year after the switch and by 0.14 HAQ 
units (95% CI 0.04 to 0.25) 3 years after the switch. Signiﬁ cant 
predictors for functional deterioration were high baseline levels 
of functional disability (p<0.001), older age (p=0.03), high dis-
ease activity (p=0.03) and a trend for a more favourable evolu-
tion with concomitant use of steroid (p=0.07).
DISCUSSION
In the absence of any trial directly comparing the efﬁ cacy of RTX 
and an alternative anti-TNF agent,26 we analysed the effective-
ness of switching to an alternative anti-TNF agent versus RTX 
on long-term outcomes in a longitudinal cohort study. After 
adjusting for potential confounders, we found no signiﬁ cant 
differences in the rates of erosion progression between patients 
taking an alternative anti-TNF agent and patients taking RTX. 
The longitudinal progression of functional disability (HAQ) sug-
gested an advantage for patients treated with RTX compared to 
patients treated with an alternative anti-TNF agent.
Previous observational studies have generally suggested that 
biological agents with a different mechanism of action, such as 
Figure 3 Change in functional disability after the initiation of an 
alternative tumour necrosis factor (TNF) inhibitor versus rituximab 
(RTX). The change in functional disability (Health Assessment 
Questionnaire Disability Index (HAQ-DI)) from baseline over the 
average follow-up period is represented for patients treated with 
RTX (open diamond with a red line across) or with an alternative 
TNF inhibitor (alternative anti-TNF agent: open square with a black 
line across). The progression trajectories depicted are adjusted 
for baseline disease characteristics, baseline HAQ-DI scores and 
treatment characteristics. Vertical lines represent the 95% CI of the 
mean for the anti-TNF group. Alternative anti-TNF agent represents a 
second, third or fourth TNF inhibitor.
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RTX, are more effective on disease activity than an alternative 
anti-TNF agent in patients with RA who experienced inadequate 
response to a previous anti-TNF agent.4–11 However, there has 
been a concern that RTX might not be as effective in preventing 
radiographic damage as anti-TNF agents. While we could con-
ﬁ rm the relative beneﬁ t of RTX over alternative anti-TNF agents 
on disease activity, we found a similar rate of radiographic 
erosion progression between these two treatments. Given the 
established disconnect between inﬂ ammation control and radio-
graphic damage progression with biological agents,13 this is not 
surprising. However, because of the limited sample size and fol-
low-up, we cannot exclude the possibility that minor differences 
could appear over time, yet large differences in radiographic ero-
sion progression between these agents appear very unlikely. We 
found no evidence for an effect modiﬁ cation by RF seropositiv-
ity, in contrast with what has been suggested for RTX.27 The 
improved effectiveness of RTX in seropositive patients has been 
established only for disease activity but not for radiographic 
progression or compared to other biological agents. Comparing 
our results to those of RCTs is difﬁ cult, as they involve very dif-
ferent patient populations, treatment designs and scoring meth-
ods. Nevertheless, our results conﬁ rm the effectiveness of these 
biological agents in halting radiographic disease progression, 
independently of their impact on disease activity.
The difference in the evolution of functional disability was 
unexpected, as functional disability in RA is thought to be related 
to underlying structural joint damage. However, disease activity 
may greatly inﬂ uence the assessment of functional capacity par-
ticularly in early disease,28 which would explain the beneﬁ cial 
trend in the RTX group, as this agent has a more favourable 
impact on RA disease activity in this setting.4–11
Observational studies have inherent limitations when compar-
ing the effectiveness of different treatment options. Selection bias 
may arise because assignment to these agents is not performed 
randomly. In fact, patients taking RTX were more often RF ‘sero-
positive’, had higher DAS28 levels at baseline and had failed 
more biotreatments before switching. While we could adjust for 
these differences using multivariate regression models, we can-
not exclude some degree of residual confounding or confounding 
by unmeasured factors such as a carryover effect of the previ-
ous anti-TNF agent. However, major selection bias is unlikely, 
as the choice of an alternative biotreatment is currently still 
essentially a matter of the physician’s personal preference (there 
are no ‘treatment guidelines’ for Swiss rheumatologists) and can 
thus be considered largely at random. The primary end point of 
this analysis was radiographic erosion progression as measured 
by the Ratingen scoring method,20 which implies that we could 
not assess the relative beneﬁ t of these treatments on joint space 
narrowing or cartilage degradation. Having incomplete data is 
another limitation of observational studies (ie, anti-citrullinated 
protein antibody status was available for only 50% of patients). 
Of all patients receiving an alternative biological agent after a 
prior inadequate response to an anti-TNF agent in the SCQM-RA 
cohort, 43% did not have at least two sets of consecutive radio-
graphs. Excluded patients initiated their biotreatment signiﬁ -
cantly later, suggesting that missing radiographs were mainly due 
to insufﬁ cient follow-up time and were not related to treatment 
outcome. To further limit the potential for bias by selective loss 
to follow-up, we chose to deﬁ ne drug exposure at baseline, inde-
pendently of whether patients remained on treatment (ie, intent-
to-treat analysis). Overall drug retention was not different in the 
two groups of patients. This study was not powered to examine 
safety parameters, which were not examined. Furthermore, it is 
difﬁ cult to determine whether the biological agents have been 
used optimally. Some patients might have beneﬁ tted from an 
earlier retreatment with RTX or from higher doses of anti-TNF 
agents. In particular, RTX retreatment is frequently delayed as 
most physicians still wait for a disease ﬂ are prior to administer-
ing another cycle of RTX. However, these results represent ‘real-
world’ clinical practice with these agents.
After the failure of an anti-TNF agent, the rationale for switch-
ing to biological agents with a different mode of action is to 
surmount problems related to class. In patients who have persis-
tent active disease despite anti-TNF treatment, previous studies 
suggested that a biological agent with a different mechanism 
of action may be more effective in controlling disease activity; 
however, this does not appear to result in a signiﬁ cant differ-
ence in joint erosions. Overall, our data suggest that RTX is at 
least equivalent to alternative anti-TNF agents on long-term out-
comes of RA. In conclusion, these results indicate that a biologi-
cal agent with a different mechanism of action, such as RTX, can 
be a very effective therapeutic alternative for patients who have 
responded inadequately to previous anti-TNF treatments.
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